ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling
Andrew D Wood, Edwin Chen, Ian J Donaldson, Shilpa Hattangadi, Karly A Burke, Mark A Dawson, Diego Miranda-Saavedra, Harvey F Lodish, Anthony R Green, Berthold Goettgens
BLOOD | AMER SOC HEMATOLOGY | Published : 2009
The discovery of JAK2V617F as an acquired mutation in the majority of patients with myeloproliferative disorders (MPDs) and the key role of the JAK2-STAT5 signaling cascade in normal hematopoiesis has focused attention on the downstream transcriptional targets of STAT5. Despite evidence of its vital role in normal erythropoiesis and its ability to recapitulate many of the features of myeloid malignancies, including the MPDs, few functionally validated targets of STAT5 have been described. Here we used a combination of comparative genomics and chromatin immunoprecipitation assays to identify ID1 as a novel target of the JAK2-STAT5 signaling axis in erythroid cells. STAT5 binds and transactiva..View full abstract
Awarded by Medical Research Council
Awarded by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
We gratefully acknowledge the assistance of Jacinta Carter and Tina Hamilton for help with animal work, and Simon McCallum and Anna Petrunkina for help with flow cytometry.Work in the authors' laboratories is supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Center, the Leukemia & Lymphoma Society, Cancer Research UK, and the Leukemia Research Fund.